Overall, Administration, rated as ?Outstanding? in the 2010 Summary Statement, holds the responsibility for managing and coordinating all financial and operational functions related to the strategic vision of the OSUCCC and CCSG. With Dr. Caligiuri assuming responsibilities as the OSUCCC Director as well as the CEO of the James Cancer Hospital in 2008, Administration was re-organized in 2010 in a similar fashion in order to integrate the administrative leadership to better facilitate the clinical and translational research mission of the OSUCCC. Further, the key roles that Administration now plays have grown considerably and are fully integrated across the Medical Center and the University to ensure the OSUCCC and CCSG needs are represented, prioritized and facilitated in an effective manner. Also in the 2010 Summary Statement, the reviewers rated Senior Leadership ?Exceptional?. Dr. Caligiuri now enters his 12th year as the OSUCCC Director and his 7th year as CEO of The James Cancer Hospital overseeing the entire cancer program at The Ohio State University. As the Director of the OSUCCC, Dr. Caligiuri has direct reporting to the Provost of the University and as CEO of the James Cancer Hospital he has direct reporting to the President of the University. To operate most effectively, Dr. Caligiuri has established a leadership structure with three key leadership positions directly reporting to him, the Senior Executive Director for Administration, the Deputy Director and the Physician-in-Chief. This executive team along with the Associate Directors of Basic Science, Clinical Research, Population Science, Biospecimen Research and Shared Resources as well as the Directors of Research Operations, Clinical Research Administration and Information Technology make up the core OSUCCC Senior Leadership Team. Now as the OSUCCC enters its 39TH year, the Senior Leadership team with Administration is responsible for coordinating the strategic growth of the Center, including facilitation of outstanding basic research programs, inter- and intra-programmatic collaboration, guiding translational and clinical research efforts, education and community outreach and provision of appropriate Shared Resource facilities. The team is also responsible for developing and executing long-term vision and strategic planning for the OSUCCC, and working towards the NCI goal to reduce morbidity and mortality from cancer. The changes that have occurred during the last funding cycle have been dramatic in terms of growth. Nonetheless, the path and vision set by the Director are for continued expansion of scientific discovery and translational research remains, with emphasis on our core strengths in cancer genetics, experimental therapeutics and prevention. Throughout this current cycle, Senior Leadership and Administration have worked together successfully to coordinate efforts and achieve several key accomplishments in support of the mission of the OSUCCC and CCSG.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016058-41
Application #
9221245
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2016-12-01
Budget End
2017-11-30
Support Year
41
Fiscal Year
2017
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Miller, Eric D; Fisher, James L; Haglund, Karl E et al. (2018) Identifying patterns of care for elderly patients with non-surgically treated stage III non-small cell lung cancer: an analysis of the national cancer database. Radiat Oncol 13:196
Fenn, J Daniel; Johnson, Christopher M; Peng, Juan et al. (2018) Kymograph analysis with high temporal resolution reveals new features of neurofilament transport kinetics. Cytoskeleton (Hoboken) 75:22-41
Colombo, Mara; Lòpez-Perolio, Irene; Meeks, Huong D et al. (2018) The BRCA2 c.68-7T > A variant is not pathogenic: A model for clinical calibration of spliceogenicity. Hum Mutat 39:729-741
Hendricks, William P D; Zismann, Victoria; Sivaprakasam, Karthigayini et al. (2018) Somatic inactivating PTPRJ mutations and dysregulated pathways identified in canine malignant melanoma by integrated comparative genomic analysis. PLoS Genet 14:e1007589
Gardner, Heather L; Rippy, Sarah B; Bear, Misty D et al. (2018) Phase I/II evaluation of RV1001, a novel PI3K? inhibitor, in spontaneous canine lymphoma. PLoS One 13:e0195357
Barnhouse, Victoria R; Weist, Jessica L; Shukla, Vasudha C et al. (2018) Myoferlin regulates epithelial cancer cell plasticity and migration through autocrine TGF-?1 signaling. Oncotarget 9:19209-19222
Chen, Luxi; Youssef, Youssef; Robinson, Cameron et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity 49:464-476.e4
Di Marcantonio, Daniela; Martinez, Esteban; Sidoli, Simone et al. (2018) Protein Kinase C Epsilon Is a Key Regulator of Mitochondrial Redox Homeostasis in Acute Myeloid Leukemia. Clin Cancer Res 24:608-618
Pettit, Cory; Webb, Amy; Walston, Steve et al. (2018) MicroRNA molecular profiling identifies potential signaling pathways conferring resistance to chemoradiation in locally-advanced rectal adenocarcinoma. Oncotarget 9:28951-28964
Walker, Christopher J; Oakes, Christopher C; Genutis, Luke K et al. (2018) Genome-wide association study identifies an acute myeloid leukemia susceptibility locus near BICRA. Leukemia :

Showing the most recent 10 out of 2602 publications